Breast cancer heterogeneity determines cancer progression, treatment effects, and
prognosis. However, the precise mechanism for this heterogeneity remains unknown owing …

The HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) is approved
for the treatment of metastatic, HER2-positive breast cancer after prior trastuzumab and …

Abnormal alterations in human epidermal growth factor receptor 2 (HER2, neu, and erbB2)
are associated with the development of many tumors. It is currently a crucial treatment for …

Targeted drug delivery has improved cancer treatment significantly in recent years, although
it is difficult to achieve. Different approaches have been developed to apply targeted drug …

Antibody-drug conjugates (ADCs) represent a novel and promising approach in targeted
therapy, uniting the specificity of antibodies that recognize specific antigens with payloads …

Uterine carcinosarcoma (UCS) is a biphasic aggressive high-grade endometrial cancer in
which the sarcoma element has de-differentiated from the carcinoma element. UCS is …

The approval of ado-trastuzumab emtansine (T-DM1) for clinical use represented a turning
point both in HER2-positive breast cancer treatment and antibody–drug conjugate (ADC) …

Context.—Endometrial serous carcinoma is an aggressive subtype of endometrial cancer
with the highest rate of recurrence and mortality among all histotypes. A recent clinical trial …

Duocarmycins are a class of DNA minor-groove-binding alkylating molecules. For the past
decade, various duocarmycin analogues have been used as payloads in the development …

S-adenosylmethionine (SAM) is ubiquitous in living organisms and is of great significance in
metabolism as a cofactor of various enzymes. Methyltransferases (MTases), a major group …